Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices
September 8th, 2023
1.5K views
Here, we describe the technique for the microsurgical creation of giant bifurcation aneurysms in rabbits for the evaluation of endovascular devices.
Overview
This study outlines a microsurgical technique to create giant bifurcation aneurysms in rabbits, aimed at advancing the evaluation of endovascular devices. The developed model offers a reliable platform for assessing treatments for giant aneurysms, which are challenging to manage in humans.
Key Study Components
Area of Science
- Neurosurgery
- Vascular biology
- Endovascular therapy
Background
- Giant aneurysms are critical conditions in human patients.
- Current animal models for studying these aneurysms are limited.
- Development of new devices for aneurysm treatment requires reliable models.
- This technique aims to minimize morbidity and enhance aneurysm patency rates.
Purpose of Study
- Create a microsurgical training model for giant bifurcation aneurysms.
- Facilitate clinical research on endovascular devices.
- Ensure high comparability of the model to human conditions.
Methods Used
- Microsurgical techniques were performed on a rabbit model.
- Giant bifurcation aneurysms were created via specific vascular interventions.
- Post-operative care included administration of anticoagulants.
- The procedure maintained 0% mortality and high patency in generated aneurysms.
Main Results
- The technique achieved successful creation of aneurysms with measured lengths and neck widths.
- Device implantation was possible, allowing for further research and evaluation of occlusion rates.
- Histopathological analysis can lead to better understanding of the lesion pathology.
- Demonstrated effectiveness in creating a reliable model for studying aneurysm behaviors.
Conclusions
- The study provides a validated approach for using rabbit models in aneurysm research.
- This model enhances the assessment of endovascular devices and their mechanisms.
- Outcomes could inform future therapeutic strategies for giant aneurysms in humans.
Frequently Asked Questions
What are the advantages of this technique?
It offers a true bifurcation design for modeling giant aneurysms with minimal morbidity and high patency rates.
How is the animal model implemented?
The model involves microsurgical creation of bifurcation aneurysms in rabbits following a detailed surgical protocol.
What outcomes can be measured with this model?
Outcomes include patency rates of aneurysms and the performance of implanted endovascular devices.
Can the technique be adapted for other research purposes?
Yes, it can be used for testing various endovascular devices and understanding aneurysm pathology.
What are the limitations of this model?
While effective, the model remains specific to rabbits and may not fully replicate human conditions.
What post-operative care is required for the rabbits?
Post-operative care includes anticoagulant treatment and monitoring for potential complications.
How can this research contribute to clinical practices?
It provides insights into device behaviors and aneurysm treatment strategies that could improve patient outcomes.
Executive Industry Relevance
Reliable in vivo models for giant bifurcation aneurysms are essential for preclinical evaluation of endovascular devices targeting high-risk vascular lesions. This microsurgical rabbit model enables translational assessment of device performance, occlusion rates, and biological compatibility under clinically relevant hemodynamic conditions. The approach supports predictive confidence and de-risking at the device discovery and validation inflection point.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of device-tissue interactions in a controlled, disease-relevant system.
- Supports functional validation of endovascular device concepts prior to clinical translation.
- Facilitates biological de-risking by modeling human-like hemodynamics and coagulation.
Screening & Assay Development
- Provides a standardized, reproducible platform for quantitative assessment of device occlusion and patency rates.
- Enables comparative evaluation of multiple device prototypes under uniform conditions.
- Supports assay development for imaging, histopathology, and device integration endpoints.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling MR imaging and histopathological correlation.
- Ensures continuity from device discovery through preclinical validation in a model with high human comparability.
- Supports risk-adjusted advancement decisions for device candidates based on robust in vivo data.
Pipeline & Workflow Integration
This model bridges early device discovery, lead identification, and preclinical validation for endovascular technologies targeting giant aneurysms.
- Discovery Biology: Supports hypothesis testing of device mechanisms and biological responses in a relevant vascular context.
- Screening: Delivers reproducible, quantitative readouts for device performance and aneurysm patency.
- Analytics: Enables measurement of occlusion rates, imaging endpoints, and histopathological outcomes for cross-device comparison.
- Translational Research: Facilitates alignment with clinical imaging and pathology standards for translational continuity.
- Enterprise Reuse: Establishes a reusable, validated animal model for ongoing device evaluation and optimization.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in device efficacy and safety prior to clinical studies.
- Operational Value: Standardizes preclinical workflows and enhances reproducibility across device programs.
- Strategic Value: Improves go/no-go decision-making and capital allocation for device portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of high-potential endovascular technologies.
Implementation Considerations
- Requires microsurgical expertise and access to specialized animal surgical facilities.
- Demands imaging and histopathological infrastructure for endpoint analysis.
- Necessitates cross-team standardization of surgical and analytical protocols.
- Adaptation to other species or vascular territories may require protocol modification.
- Model limitations include species-specific differences and scalability constraints.
Biopharma FAQs
Why does null hypothesis testing matter for device validation in this aneurysm model?
Null hypothesis testing enables objective evaluation of whether endovascular devices achieve statistically significant improvements in occlusion or patency rates compared to controls, supporting robust target validation and portfolio triage.
How does independent variable isolation fit the bifurcation aneurysm device pipeline?
Isolating device-specific variables in this model allows teams to attribute observed outcomes directly to device design or deployment, reducing confounding and increasing mechanistic clarity during early discovery and screening.
What do quantitative dependent variable measurements enable in this model?
Quantitative measurements of aneurysm patency, occlusion rates, and imaging endpoints provide actionable data for comparing device candidates and informing advancement decisions in the preclinical pipeline.
Why are replication requirements critical for cross-functional device development?
Replication ensures that device performance and biological responses are consistent across experiments, enabling reliable cross-team data sharing and supporting regulatory and translational milestones.
What statistical analysis capabilities are required before device implementation in this model?
Robust statistical analysis is needed to compare device groups, assess significance of outcomes, and validate reproducibility, forming the basis for go/no-go decisions and further development investment.
